It's both a fact and a myth. As I said, no two regimes are alike. Canada is the only country with a universal health care system that doesn't include prescription drug coverage. Therefore, the idea was that we would try to approximate what we would be able to secure by way of our monopsony power, if we were buying on behalf of the total population, by creating a ceiling price regulator.
There is no other country that has a ceiling price regulator in this sector like Canada does, but the new economic factors that we're adopting as part of these regulatory changes are based on pharmacoeconomic value, market size/affordability and based on best practices internationally. I'm not aware of any country where these things are not given prominence in the process for determining whether to reimburse a drug and at what price.